Unique ID issued by UMIN | UMIN000003898 |
---|---|
Receipt number | R000004685 |
Scientific Title | A randomized study of the influence of proton pump inhibitors on antiplatelet effect by Clopidogrel based on CYP2C19 genotypes |
Date of disclosure of the study information | 2010/07/20 |
Last modified on | 2010/07/20 11:05:09 |
A randomized study of the influence of proton pump inhibitors on antiplatelet effect by Clopidogrel based on CYP2C19 genotypes
CYP2C19, Clopidgrel and Proton Pump Inhibitor Estimation study(CYCLON study)
A randomized study of the influence of proton pump inhibitors on antiplatelet effect by Clopidogrel based on CYP2C19 genotypes
CYP2C19, Clopidgrel and Proton Pump Inhibitor Estimation study(CYCLON study)
Japan |
Angina pectoris and myocardial infarction
Medicine in general | Cardiology |
Others
YES
We hypothesized that proton pomp inhibitors may affect antiplatelet effect by clopidogrel based on CYP2C19 genotypes in patients with coronary artery disease.
Efficacy
Exploratory
Inhibitory effect of anti-platelet aggregation estimated by phosphorytation of VASP after administration of clopidgrel and proton pump inhibitors
relationship between CYP2C19 genotypes and the effect of proton pump inhibitors on anti-platelet aggregation by clopidgrel
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
3
Treatment
Medicine |
Study patients are randomized into three groups according to proton pump inhibitors administration.
a) Rabeprazole 10mg
b) Lansoprazole 30mg
c) Omeprazole 20mg
Not applicable |
Not applicable |
Male and Female
The patient with angina pectoris or myocardial infarction, who underwent de novo coronary stent implantation
1) the patient of severe liver disease
2) the patient of severe renal disease
3) the patient of congenital heart disease
4) the patient of myocardial infarction within 3 months from onset or of severe cardiac function
5) the patient of endocrine disease
6) the patient of malignant or inflammatory disease
7) the patient of severe respiratory disease including idiopathic pulmonary artery hypertension
8) the patient of impaired activities of daily living by neurological or orthopedic disease
9) the patient of severe hypertension
10) the patient who taking corticosteroid or immunosuppressive drug
11) the patient of type 1 diabetes mellitus
12) the patient pregnant or probable of pregnancy
13) the catecholamine injected patient
14) the patient of symptomatic hypotension
15) the patient with left ventricular outflow tract obstruction, hypertrophic obstructive cardiomyopthy or aortic stenosis, effecting hemodynamics significantly
16) the patient who is judged inappropriate for any reason by doctor
150
1st name | |
Middle name | |
Last name | Nonogi Hiroshi |
National Cerebral and Cardiovascular center
Division of cardiology, Department of Medicine
5-7-1 Fujishirodai, Suita, Osaka, Japan
06-6833-5012
1st name | |
Middle name | |
Last name | Noguchi Teruo |
National Cerebral and Cardiovascular center
Division of cardiology, Department of Medicine
5-7-1 Fujishirodai, Suita, Osaka, Japan
06-6833-5012
tnoguchi@hsp.ncvc.go.jp
National Cerebral and Cardiovascular Center
National Cerebral and Cardiovascular Center
Other
Japan
NO
2010 | Year | 07 | Month | 20 | Day |
Unpublished
Preinitiation
2009 | Year | 10 | Month | 20 | Day |
2010 | Year | 07 | Month | 01 | Day |
2010 | Year | 07 | Month | 09 | Day |
2010 | Year | 07 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004685